Twist Bioscience Corp Poised for Earnings Call: A Comprehensive Analysis

August 28, 2023


Twist Bioscience Corp, a leading synthetic biology company, is gearing up to release its financial results for the third quarter of 2023. As investors eagerly await the upcoming earnings call on August 4th, 2023, at 8:00 AM EST, analysts and market observers are delving into various aspects of the company’s performance to provide a comprehensive assessment. In this article, we will explore fundamental and technical analysis, historical guidance, and analysts’ estimates to give readers a well-rounded view of what to expect from Twist Bioscience Corp.

Fundamental Analysis:

ReportDate NetIncome TotalRevenue DilutedEPS unit
Q3 2023-06-30 -57.4 63.7 -1.01 million USD
Q2 2023-03-31 -59.2 60.2 -1.04 million USD
Q1 2022-12-31 -41.8 54.2 -0.74 million USD
Q4 2022-09-30 -51.1 57.3 -0.91 million USD
Q3 2022-06-30 -60.5 56.1 -1.08 million USD

Twist Bioscience Corp has been experiencing negative net income over the past year, with Q3 2023 showing a net loss of $57.4 million. However, it is essential to note that the company’s total revenue has been steadily increasing, reaching $63.7 million in the last quarter. This remarkable revenue growth indicates the potential for future profitability.

The negative Diluted Earnings Per Share (EPS) raises concerns for some investors. However, it is important to analyze Twist Bioscience Corp‘s position in the synthetic biology industry and its efforts towards research and development. The company’s continual investment in innovation and its expanding product portfolio could be indicative of future revenue growth and improved profitability.

Technical Analysis:

since low high change change%
1D 2023-08-25 19.0 19.9 0.6 3.1
5D 2023-08-21 19.0 20.5 0.4 2.1
1M 2023-07-27 18.2 27.4 -5.1 -20.5
3M 2023-05-30 14.3 27.4 4.6 30.2

Analyzing Twist Bioscience Corp‘s recent price performance provides insights into market sentiment and investor behavior. Over the past three months, the stock has shown significant volatility, with a high of $27.4 and a low of $14.3. Despite the recent dip in stock price, there has been a positive trend in the short term, with a 3.1% increase over one day and a 2.1% increase over five days.

The 30.2% increase in stock price over the last three months suggests that investors have been optimistic about the company’s growth potential. However, the recent 20.5% decline in the past month warrants a closer look during the earnings call. Technical analysis indicates that market sentiment has been mixed, highlighting the importance of the upcoming earnings call in providing clarity and reassurance to investors.

Historical Guidance:

Twist Bioscience Corp‘s historical financial data reveals a pattern of revenue growth over the past year, reflecting the company’s ability to capture market demand for its synthetic DNA solutions. Despite consistent net losses, the firm has managed to increase its total revenue from $56.1 million in Q3 2022 to $63.7 million in Q3 2023.

This consistent growth aligns with Twist Bioscience Corp‘s strategic vision and investment in research and development initiatives. By expanding its product offerings and focusing on increasing customer adoption, the company has positioned itself for future success. The earnings call will likely shed further light on how effectively Twist Bioscience Corp plans to monetize its expanding customer base.

Analysts’ Estimates:

Leading up to the earnings call, sentiment among analysts has been predominantly positive. Analyst estimates will play a crucial role in shaping investors’ expectations for Twist Bioscience Corp‘s financial performance in Q3 2023. However, it is important to consider the broader market landscape, potential industry challenges, and macroeconomic factors that could influence these estimates.

The positive sentiment surrounding Twist Bioscience Corp stems from its pioneering position in the synthetic biology industry and its strong revenue growth. Analysts will be closely monitoring the company’s progress in expanding its customer base, partnerships, and revenue-generating capabilities.


As we approach the highly anticipated earnings call, Twist Bioscience Corp remains an intriguing case study for investors interested in synthetic biology and innovation-driven companies. While the company has experienced negative net income and dilution in EPS, its consistent revenue growth and expanding product portfolio indicate promising long-term potential.

By considering the insights derived from fundamental and technical analyses, historical guidance, and analysts’ estimates, investors can make informed decisions ahead of the earnings call. The upcoming financial results and management commentary during the call will provide valuable insights into Twist Bioscience Corp‘s ongoing initiatives, growth prospects, and ability to navigate market challenges.

Investors and industry enthusiasts alike should mark their calendars for August 4th, 2023, at 8:00 AM EST, to gain a deeper understanding of Twist Bioscience Corp‘s financial performance and future trajectory. The unique nature of Twist Bioscience Corp‘s synthetic biology solutions presents tremendous opportunities for innovation-driven growth, making it an exciting company to watch in the coming quarters and beyond.

Recent Posts

Leave a Comment